X

Sign up for Equitymaster's free daily newsletter, The 5 Minute WrapUp and get access to our latest Multibagger guide (2018 Edition) on picking money-making stocks.

This is an entirely free service. No payments are to be made.


Download Now Subscribe to our free daily e-letter, The 5 Minute WrapUp and get this complimentary report.
We hate spam as much as you do. Check out our Privacy Policy and Terms Of Use.
Compare ASTRAZENECA PHARMA with Natco Pharma - Equitymaster

Helping You Build Wealth With Honest Research
Since 1996. Try Now

  • MyStocks

MEMBER'S LOGINX

     
Login Failure
   
     
   
     
 
 
 
(Please do not use this option on a public machine)
 
     
 
 
 
  Sign Up | Forgot Password?  

ASTRAZENECA PHARMA vs NATCO PHARMA - Comparison Results

ASTRAZENECA PHARMA    Change

AstraZeneca Pharma India Limited (APIL) is a 90% subsidiary of the UK based AstraZeneca Pharmaceuticals, which is one of the world's leading pharma companies. APIL has interests in the six crucial areas of cardiovascular, respiratory, maternal health... More

DO YOU LIKE THESE REPORTS? TELL US!

Current Valuations

    ASTRAZENECA PHARMA NATCO PHARMA ASTRAZENECA PHARMA/
NATCO PHARMA
 
P/E (TTM) x 159.7 13.9 1,145.2% View Chart
P/BV x 24.8 4.0 621.8% View Chart
Dividend Yield % 0.0 1.1 -  

Financials

 ASTRAZENECA PHARMA   NATCO PHARMA
EQUITY SHARE DATA
    ASTRAZENECA PHARMA
Mar-14
NATCO PHARMA
Mar-18
ASTRAZENECA PHARMA/
NATCO PHARMA
5-Yr Chart
Click to enlarge
High Rs1,2851,080 119.0%   
Low Rs634671 94.4%   
Sales per share (Unadj.) Rs189.6592.1 32.0%  
Earnings per share (Unadj.) Rs-0.2188.4 -0.1%  
Cash flow per share (Unadj.) Rs3.8206.3 1.9%  
Dividends per share (Unadj.) Rs08.25 0.0%  
Dividend yield (eoy) %00.9 0.0%  
Book value per share (Unadj.) Rs68.6833.6 8.2%  
Shares outstanding (eoy) m25.0036.90 67.8%   
Bonus/Rights/Conversions -IS-  
Price / Sales ratio x5.11.5 342.2%   
Avg P/E ratio x-4,712.74.6 -101,395.8%  
P/CF ratio (eoy) x249.64.2 5,881.3%  
Price / Book Value ratio x14.01.1 1,330.8%  
Dividend payout %04.4 0.0%   
Avg Mkt Cap Rs m23,98832,311 74.2%   
No. of employees `0001.64.8 32.3%   
Total wages/salary Rs m1,6053,256 49.3%   
Avg. sales/employee Rs Th3,040.24,522.5 67.2%   
Avg. wages/employee Rs Th1,029.2674.0 152.7%   
Avg. net profit/employee Rs Th-3.31,439.0 -0.2%   
INCOME DATA
Net Sales Rs m4,74021,848 21.7%  
Other income Rs m92404 22.8%   
Total revenues Rs m4,83222,252 21.7%   
Gross profit Rs m-1309,284 -1.4%  
Depreciation Rs m101662 15.3%   
Interest Rs m0154 0.0%   
Profit before tax Rs m-1398,872 -1.6%   
Minority Interest Rs m00-   
Prior Period Items Rs m00-   
Extraordinary Inc (Exp) Rs m1390-   
Tax Rs m51,920 0.3%   
Profit after tax Rs m-56,952 -0.1%  
Gross profit margin %-2.742.5 -6.4%  
Effective tax rate %-3.721.6 -16.9%   
Net profit margin %-0.131.8 -0.3%  
BALANCE SHEET DATA
Current assets Rs m2,72621,307 12.8%   
Current liabilities Rs m2,4355,920 41.1%   
Net working cap to sales %6.170.4 8.7%  
Current ratio x1.13.6 31.1%  
Inventory Days Days7473 100.7%  
Debtors Days Days41107 38.3%  
Net fixed assets Rs m1,03514,986 6.9%   
Share capital Rs m50369 13.6%   
"Free" reserves Rs m94230,353 3.1%   
Net worth Rs m1,71630,760 5.6%   
Long term debt Rs m00-   
Total assets Rs m4,15637,151 11.2%  
Interest coverage xNM58.6-  
Debt to equity ratio x00-  
Sales to assets ratio x1.10.6 193.9%   
Return on assets %-0.119.1 -0.6%  
Return on equity %-0.322.6 -1.3%  
Return on capital %029.3 0.0%  
Exports to sales %5.70-   
Imports to sales %6.50-   
Exports (fob) Rs m270NA-   
Imports (cif) Rs m306NA-   
Fx inflow Rs m37510,322 3.6%   
Fx outflow Rs m4702,978 15.8%   
Net fx Rs m-967,343 -1.3%   
CASH FLOW
From Operations Rs m-84,636 -0.2%  
From Investments Rs m-146-11,155 1.3%  
From Financial Activity Rs m8626,509 13.2%  
Net Cashflow Rs m709-18 -3,936.1%  

Share Holding

Indian Promoters % 0.0 52.0 -  
Foreign collaborators % 75.0 1.5 5,102.0%  
Indian inst/Mut Fund % 0.3 7.8 3.8%  
FIIs % 15.7 16.6 94.4%  
ADR/GDR % 0.0 0.0 -  
Free float % 9.1 26.0 35.0%  
Shareholders   12,856 25,395 50.6%  
Pledged promoter(s) holding % 0.0 0.0 -  
NM: Not Meaningful
Source: Company Annual Reports, Regulatory Filings, Equitymaster

Compare ASTRAZENECA PHARMA With:   ALEMBIC LTD  AUROBINDO PHARMA  IPCA LABS  FDC LTD.  SUN PHARMA  

Compare ASTRAZENECA PHARMA With:   ACTAVIS (US)  ADCOCK INGRAM (S. Africa)  MYLAN (US)  TEVA PHARMA (Israel)  



Today's Market

Sensex Ends 331 Points Higher; Oil & Gas Stocks Witness Buying(Closing)

After opening on a negative note, share markets in India witnessed buying interest during closing hours and ended the day on a positive note.

Related Views on News

NATCO PHARMA Announces Quarterly Results (2QFY19); Net Profit Up 115.2% (Quarterly Result Update)

Nov 12, 2018 | Updated on Nov 12, 2018

For the quarter ended September 2018, NATCO PHARMA has posted a net profit of Rs 2 bn (up 115.2% YoY). Sales on the other hand came in at Rs 5 bn (up 27.4% YoY). Read on for a complete analysis of NATCO PHARMA's quarterly results.

ASTRAZENECA PHARMA Announces Quarterly Results (1QFY19); Net Profit Up 10.3% (Quarterly Result Update)

Aug 21, 2018 | Updated on Aug 21, 2018

For the quarter ended June 2018, ASTRAZENECA PHARMA has posted a net profit of Rs 64 m (up 10.3% YoY). Sales on the other hand came in at Rs 2 bn (up 25.7% YoY). Read on for a complete analysis of ASTRAZENECA PHARMA's quarterly results.

Aster DM Healthcare (IPO)

Feb 10, 2018

Should you subscribe to the IPO of Aster DM Healthcare Ltd?

Dr Reddy's: Milestone Payment Drives Sales (Quarterly Results Update - Detailed)

Feb 9, 2018

US business was hit by pricing pressure although there was growth sequentially led by new product launches.

Lupin: US market Declines Due to Higher Base Effect of FY17 (Quarterly Results Update - Detailed)

Feb 9, 2018

Price erosion in generic US drugs continues but seems to be bottoming out.

More Views on News

Most Popular

3 Big Money Makers to Round Out Your 2018 Portfolio(Profit Hunter)

Oct 31, 2018

The market is offering many strong opportunities in the small cap space right now. Don't miss out. This is the time to get rich.

These Are the Kind of Blue Chips You Should Invest In(The 5 Minute Wrapup)

Nov 9, 2018

All blue chip companies are large caps but all large caps are not blue chips.

Insider Buying: These Owner Operators Are Taking Advantage of the Correction(Chart Of The Day)

Nov 2, 2018

We believe insider buying is one of the strongest smart money indicators.

Are You Among The 35% Parents Who Will Not Be Able To Finance Their Child's Future?(Outside View)

Nov 1, 2018

PersonalFN explains the importance of being prepared for your child's future.

Are Fund Houses Opening Up Their NFO Factories Again?(Outside View)

Nov 2, 2018

PersonalFN sheds light on FY 2018-19 so far, the mutual fund industry has collectively launched 84 New Fund Offers (NFOs), of which some are still open for subscription.

More

Small Investments
BIG Returns

Zero To Millions Guide 2018
Get our special report, Zero To Millions
(2018 Edition) Now!
We will never sell or rent your email id.
Please read our Terms

ASTRAZENECA PHARMA SHARE PRICE


Nov 13, 2018 (Close)

TRACK ASTRAZENECA PHARMA

  • Track your investment in ASTRAZENECA PHARMA with Equitymaster's Portfolio Tracker. Set live price alerts, get research alerts and more. Get access now...
  • Add To MyStocks

MORE ON ASTRAZENECA PHARMA

ASTRAZENECA PHARMA 8-QTR ANALYSIS

COMPARE ASTRAZENECA PHARMA WITH

MARKET STATS